Matteo Lambertini, MD PhD· @matteolambe · X·· 1 day agoScore45
Body · original
Oral abstract #BreastCancer session at #ESMO26: no overall survival benefit with the #AKT inhibitor #ipatasertib added to #fulvestrant in patients with advanced endocrine-resistant disease
@OncoAlert @myESMO #bcsm
53 views · 3 likes · 3 reposts · 0 replies
Conference abstracts
LBA14matched by Proffered paper 2: Breast cancer, early and advanced stage
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.orgSource: Matteo Lambertini, MD PhD · x.com